Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis (Q22306318)

Europe PubMed Central

title

Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis (English)

0 references

0 references

0 references

Kelvin H.-V. Tan

1

Kelvin H-V

Tan

1 reference

PubMed

8 February 2023

Michael Mulheran

series ordinal

2

author given names

Michael

author last names

Mulheran

1 reference

PubMed

8 February 2023

Alan J. Knox

series ordinal

3

0 references

Alan R. Smyth

series ordinal

4

author given names

Alan R

author last names

Smyth

1 reference

PubMed

American Journal of Respiratory and Critical Care Medicine

8 February 2023

language of work or name

English

0 references

publication date

15 March 2003

0 references

published in

0 references

volume

167

0 references

issue

6

0 references

page(s)

819-823

0 references

cites work

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Gentamicin therapy in renal failure: a nomogram for dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Stimulation of free radical formation by aminoglycoside antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Current perspectives on inner ear toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Health of teenagers in residential care: comparison of data held by care staff with data in community child health records

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Single or multiple daily doses of aminoglycosides: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Women with cystic fibrosis and their potential for reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Aminoglycoside ototoxicity

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Individualization of tobramycin dosage in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Pharmacokinetics of tobramycin in pregnant women. Safety and efficacy of a once-daily dose regimen.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Aminoglycosides: nephrotoxicity

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Toxicity of Colistin in Cystic Fibrosis Patients

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Are measurements of urine enzymes useful during aminoglycoside therapy?

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200109-012CC

7 January 2021

10.1164/RCCM.200109-012CC

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017